Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis

Table 3 Costs, life-years and incremental cost per life-year gained

First-line treatment	Cost per loading dose (£)	Cost per maintenance dose (£)		Total costs (£)	Incremental costs (£)	Total no. life years	Incremental no. life years	Incremental cost-effectiveness ratio
First-line treatment	IV	IV	Oral	Total costs (£)	Incremental costs (£)	Total no. life years	Incremental no. life years	Incremental cost-effectiveness ratio
Anidulafungin	600.0	300.0	-	28,216	–	7.23	–	–
Fluconazole	7.8	7.8	1.4	27,646	−570	6.52	−0.70	813
Caspofungin	416.8	367.2	-	28,905	689	6.03	−1.19	Dominated^a
Micafungin	341.0	341.0	-	28,721	504	5.55	−1.68	Dominated^a

The incremental cost-effectiveness ratio calculated was the incremental cost per life year gained. All incremental cost-effectiveness ratios were calculated as anidulafungin vs comparator
^aFirst-line treatment with anidulafungin was less costly and more effective than the comparator, thus first-line treatment with anidulafungin dominated the comparator

ISSN: 1471-2334